Table 2 Baseline characteristics of participants1
Placebo (n = 69) | Probiotic (n = 65) | |
|---|---|---|
Age (s.d) | 42.7 (12.7) | 44.8 (12.1) |
Disease duration (s.d) | 20.3 (13.4) | 20.3 (13.2) |
Male (%) | 45 (65.2) | 49 (75.4) |
Iritis2 (%) | 13/58 (22.4) | 14/52 (26.9) |
Inflammatory bowel disease2 (%) | 6/58 (10.4) | 2/52 (3.9) |
Medication | ||
■ non-steroidal anti-inflammatory drug (%) | 44/66 (66.7) | 53/62 (85.5) |
■ steroid (%) | 2/67 (3.0) | 0/63 (0.0) |
■ disease modifying antirheumatic drug (%) | 8/67 (11.9) | 5/63 (7.9) |
Global Well-being (scale 0–10) | 3.2 (2.0) | 4.1 (2.5) |
Disease activity (scale 0–10) | 3.5 (1.9) | 4.1 (2.2) |
Function (scale 0–10) | 3.1 (2.5) | 4.2 (3.0) |